Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Square the circle

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Sep 26, 2023 3:04pm

131 Views

Post# 35655294

RE:RE:Square the circle

PWIB - I think the answer is all about extending duration of therapy. Too many patients drop out so the churn is too high. Easier administration in both dose and means they anticipate to enhance duration and lower churn. Ideal would be seeing both more monthly scripts, lower churn and higher duration. Any combo would immensely help revenues.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale